Current landscape
Home · Topics · Latest · Calendar · Browse tags
Selective update: November 11, 2026. The November 10 scheduled review was completed November 11, with source discovery through November 10 and focused coverage for all 32 active condition topics. Worldwide complete-topic appraisal remains incomplete.
Development stage, evidence strength and U.S. availability vary by program; the linked notes distinguish them. A category is not labeled approved merely because one treatment is available.
Metabolic health and longevity
| Topic | Current state | Next expected update |
|---|---|---|
| GLP-1 and related metabolic therapies | The retatrutide kidney registry now adds a null 24-week measured-GFR primary comparison alongside a small albuminuria signal. New oral-ecnoglutide and mazdutide type 1 diabetes protocols have no results. Trial population, formulation, analysis and safety remain separate; the October head-to-head diabetes result is retained. | Primary completion September 3, 2027; final January 28, 2028 (registry estimates). Estimated January 2027 start and March 2029 primary completion; no readout date. |
| Broad cardiovascular prevention, lipids and screening | Novartis has discontinued pelacarsen’s ASCVD program; the safety extension now records termination. HORIZON and ZEUS lowered biomarkers without demonstrated cardiovascular-event benefit in their studied secondary-prevention populations. VERVE-102 HEART-3 now lists recruiting, with an actual September start and no results. | ASCVD development discontinued; any further paper/supplement or other-indication plans have no verified date. HEART-3 primary completion August 2028 and final completion March 2030 (registry estimates). |
| Liver health and noninvasive assessment | The small CIDEB-siRNA report adds sustained 36-week liver-fat reductions, with no demonstrated histologic fibrosis reversal or fewer clinical liver events. Earlier abstracts and current analysis populations differ and remain explicitly unharmonized. Viral-hepatitis findings are cross-linked separately. | Full paper/biopsy and longer clinical-outcomes appraisal; future trial completion is distinct from publication. |
| Kidney preservation and earlier detection | Retatrutide’s short CKD study did not improve its measured-GFR primary comparison; a much smaller albuminuria analysis favored treatment, with endpoint-specific denominators and harms. MZE829’s separate APOL1-kidney HORIZON study completes enrollment, with early 2027 data forecast. Neither demonstrates prevention of kidney failure. | Full publication and longer clinical kidney-outcomes evidence: no verified date. Full HORIZON kidney data early 2027; pivotal trial H1 2027, both sponsor forecasts. |
| Longevity and healthspan trials | VITAL-H’s registered functional-healthspan protocol remains without results. A newly recovered sponsor first-dose report for SenoMune concerns advanced cancer and lacks a verified public protocol/oversight; it is not healthy-adult longevity evidence. Biomarker and animal results remain separate from human healthspan benefit. | Verified protocol/oversight and first human safety results: date unknown. |
Screening, genetics and cancer
| Topic | Current state | Next expected update |
|---|---|---|
| Whole-body MRI | A new review of heterogeneous screening cohorts estimates pathology-confirmed cancer yield but cannot establish improved patient outcomes. Downstream workups, false positives, overdiagnosis and the benefit of repeated screening remain unresolved. | Prospective controlled outcomes/repeated rounds; no announced publication date. HERCULES registry access recovered: the unchanged April 2025 record gives January 2034/January 2037 completion estimates, not announced readouts. |
| Galleri and organ-specific cancer screening | A new self-sampling delivery trial will measure screening completion and diagnostic resolution; a recovered portable-ultrasound study concerns abnormal breast examinations, not replacement of population mammography. Galleri’s early Q1 2027 FDA-decision forecast remains sponsor timing, with no new approval established. | May 2027 estimated start; December 2029 primary completion, not a promised readout. Larger programmatic validation and patient outcomes: no announced date. |
| Genetic screening and risk prediction | BRIDGES-NBS moves toward Oregon enrollment according to its laboratory partner, while Minnesota’s exact start remains planned. Feasibility, additional diagnoses and changes in management remain distinct from long-term clinical benefit; no prospective benefit from polygenic embryo selection is established. | Minnesota consenting this winter is a state forecast; exact date and longitudinal clinical-outcome readout unknown. |
| Cancer treatment, vaccines and recurrence prevention | PIKTOR plus paclitaxel shows uncontrolled responses in selected previously treated endometrial cancers, with grade ≥3 treatment-related harms in 64%. New EGFR-ADC/checkpoint Phase 3 protocols address distinct esophageal and nasopharyngeal settings. No new comparative survival benefit or U.S. approval follows from these reports. | Phase 3 planning is sponsor intent; protocol, initiation and confirmatory benefit dates unknown. Esophageal study estimated December 30, 2026 start; primary-completion forecasts late 2029, not publication dates. |
Brain, mental health and senses
| Topic | Current state | Next expected update |
|---|---|---|
| Alzheimer's screening and therapies | TARBELA-AD now lists recruitment for an oral NLRP3 inhibitor, RG6434/RO7568282, with clinical outcomes planned. CTAD will present early safety, trontinemab biomarker data and PrevenTRON design; these are separate from demonstrated cognitive or prevention benefit. Prior negative AuTonomy and sabirnetug findings remain relevant. | CTAD November 16–18 sessions; TARBELA-AD primary completion November 1, 2029 (registry estimate). |
| Psilocybin and related therapies | Compass has completed the COMP360 NDA for treatment-resistant depression; acceptance, approval and access remain separate. The Usona MDD filing report is still unconfirmed. Small new MDMA and R(-)-MDMA studies address different populations and do not establish broad efficacy or long-term safety. | FDA filing acceptance/action communication: date unknown. H1 2027 launch is conditional sponsor guidance. DT402 multiple-dosing study: 2027 sponsor forecast, unverified start. |
| Mental-health treatments, SSRIs and newer antidepressants | The second lumateperone trial reports improved acute bipolar I mania symptoms; a U.S. mania indication is still investigational. Brenipatide adds a Phase 2 adjunctive-depression protocol, with no outcomes. Neither is a new SSRI; psychedelic research remains separate. | Planned U.S. mania submission and full publication: no dates verified. Estimated November 2026 start and May 2028 primary completion; actual recruitment unverified. |
| Hearing and vision preservation/restoration | ReBUILD adds a topical bevemipretide Phase 2/3 protocol for dry AMD, with a structural primary endpoint. Inherited BEST1 research remains separate. AC102’s sudden-hearing-loss study is complete without posted outcomes; the reported 2027 plans remain unconfirmed. | Estimated November 2026 start; March 2029 primary/final completion (registry estimates). |
Sleep
The October 3 split projects existing verified coverage into five condition topics. Historical source dates and research-check gaps remain unchanged.
| Topic | Current state | Next expected update |
|---|---|---|
| Insomnia | Daridorexant has a sponsor-reported pediatric breakthrough designation; approval is still limited to adult insomnia. DARI-DREAM has begun recruiting for a distinct adult study. Guided digital CBT-I results and the SOM001 and CBD programs remain separate; no new durable architecture or safety conclusions follow. | Full Phase 2 publication undated; pediatric Phase 3 initiation H2 2027 (sponsor forecast). DARI-DREAM estimated primary completion November 22, 2027 and final December 6, 2027. |
| Obstructive sleep apnea | Monthly berobenatide’s non-PAP VESPER-OSA2 trial now lists recruitment without results. Existing LunAIRo tables clarify AD109 efficacy and harms; study withdrawal and drug discontinuation differ. AD109’s FDA action target remains February 28, 2027, with no approval inferred. | VESPER-OSA2 estimated primary June 1, 2028 and final July 20, 2028; AD109 FDA action target February 28, 2027 unchanged. |
| Narcolepsy & excessive sleepiness | DEA’s oveporexton Schedule IV rule is scheduled to publish and become effective November 12. Existing U.S. adult narcolepsy type 1 approval, actual U.S. launch and insurer coverage are separate. Japan and China launches were previously announced. | November 12 scheduled publication/effectiveness; actual U.S. launch and coverage unverified. |
| Circadian rhythm disorders | The tasimelteon jet-lag hearing now has a December 14–18 schedule. A hearing is not approval; existing circadian-disorder indications and the proposed new use remain separate. | Hetlioz jet-lag administrative hearing: 2026-12-14/2026-12-18 (Sponsor-reported scheduled hearing) |
| Restless legs syndrome | Newly recovered IV-iron and extended-duration TOMAC programs target refractory RLS and awakenings. An uncontrolled venous-ablation association does not establish a general RLS cure or causal benefit. | October2026 estimated start; April2029 primary completion. |
Physical function and immune therapies
| Topic | Current state | Next expected update |
|---|---|---|
| Muscle building and preservation | A scheduled enobosarm post-hoc function report and new COMPACT supportive-care trial keep functional outcomes separate from tissue preservation. Isembyld first U.S. infusions are now sponsor-confirmed for October; SRK-439 public data are forecast Q1 2027, not a new efficacy result. | November 16 enobosarm scheduled function analysis; Q1 2027 SRK-439 public Phase 1 data (sponsor forecasts). |
| Bone health, joint preservation and cartilage repair | ACR abstracts quantify retatrutide knee-pain improvements under efficacy estimands; they do not establish cartilage regeneration. A local-iloprost fracture-healing trial is newly registered. NVD003’s large completion-estimate change needs explanation; TG-C December timing remains unconfirmed. | Full retatrutide OA harms appraisal: date unknown. NVD003 June 2032 estimate needs clarification; TG-C December timing remains unconfirmed. |
| Non-opioid pain treatments | Alenura reports a positive acute bladder-pain Phase2 topline without effect magnitude or comparative harms. A new suzetrigine knee-replacement pilot prioritizes feasibility. Chronic neuropathy benefit remains unproven; HNK is still not yet recruiting. | Alenura full tables and filing date: unknown. HNK November 15 estimated start; suzetrigine/VX-993 DPN mid-2027 forecast unchanged. |
| Autoimmune disease and immune reset | Early ALLO-329 and NKX019 cohorts show disease-specific activity with important conditioning and denominator limits. KYSA-8’s full paper adds serious harms and a reporting discrepancy to the same SPS cohort. TOGETHER-PsA week52 uncertainty is now available, but exploratory methods and incomplete harms remain. | TOGETHER-PsA November 11 oral presentation; NKX019 H1 2027 and ALLO-329 2027 follow-up forecasts. Full miv-cel supplement appraisal is undated. |
| Allergy and airway disease | Newly tracked WIN378 is testing longer-interval TSLP blockade in asthma and COPD. Early lung-function and biomarker signals do not establish fewer severe exacerbations or long-term safety. Registry and sponsor descriptions differ on phase and enrollment. | WIN378 Phase 2 asthma week-24 results in H1 2027; COPD and asthma week-48 results in H2 2027; asthma Phase 3 in H1 2029 (sponsor forecasts). |
| Infectious-disease prevention and treatment | ECLIPSE 1 reports strong hepatitis-delta virologic suppression using its prespecified week-48 versus delayed-treatment week-12 comparison. Selected SOLSTICE withdrawal and HBV gene-editing biomarkers do not establish cure. A Shigella challenge topline lacks effect magnitude; recovered antibiotic-conjugate evidence documents infusion reactions and stopped development. | Elebsiran/tobevibart U.S. submission forecast mid-2027; PBGENE-HBV Phase 2 first dosing forecast Q1 2027. Full Shigella estimates and harms: date unknown. |
Aesthetics & Dental
| Topic | Current state | Next expected update |
|---|---|---|
| Localized fat removal and cellulite | CBL-514 has sponsor-reported clearance for a small Chinese pharmacokinetic/safety study, with enrollment forecast for December. This is separate from SUPREME Phase 3 efficacy research and supplies no marketing approval or new visceral-fat result. | Historical nerve-recovery program primary/final completion estimated December 2027; no results-release date. |
| Hair loss, restoration and graying | VDPHL01 has sponsor-reported 12-month hair gains, but placebo participants crossed to active treatment after month six. No superiority to standard minoxidil is established. New historical N1087 entries broaden the formal oral-minoxidil watch; hair-pigment programs remain separate. | Female Study 306 topline: H1 2027 sponsor forecast; approval/filing date unverified. Both starts estimated January 2027; primary completion July 2028 in women and October 2028 in men. Results-release dates unknown. |
| Skin aging, laxity and regeneration | A randomized skin-quality injection study reports short-term appearance benefit versus no treatment. New toxin-combination and tiny reversal protocols broaden the pipeline without results; reversal timing and U.S. regulatory forecasts remain uncertain. | Longer controlled durability and full registration matching: no verified readout date. Combination primary/final completion estimated June 2028. Monotherapy resubmission/decision forecast remains unconfirmed. |
| Scar prevention, treatment and stretch marks | SNT-9465 recruitment is paused after local skin irritation; an unblinded review is expected in Q4 2026 before restart or discontinuation is decided. This makes the earlier topline forecast conditional. Other scar programs remain investigational. | Q4 2026 sponsor review of unblinded tolerability; restart versus discontinuation unresolved. Prior Q1 2027 topline is conditional. |
| Facial volume restoration and contour | Two uncontrolled GLP-1 cohorts report improved facial satisfaction after aesthetic treatment; they do not demonstrate fat regeneration. A randomized temple-PLLA study adds controlled six-month appearance evidence for a specific formulation, with local reactions and limited comparative durability. | Full HALO cohort and longer-term durability/harms: no verified release date. Long-term comparative durability and independent replication: no verified release date. |
| Pigmentation and uneven skin tone | A newly registered GR2301 anti-IL-15 Phase 2 study adds to the vitiligo pipeline, without outcomes. Existing povorcitinib results and safety findings remain relevant; repigmentation thresholds do not establish cure or long-term safety. | Actual start confirmation next; primary completion estimated May 2028 and final completion November 2028. |
| Acne and rosacea | Late-posted BMX-010 rosacea observations involve only six uncontrolled participants and cannot establish efficacy. A new acne protocol keeps the retinoid background identical. Denifanstat Phase 3 topline remains forecast for H2 2027. | BMX-010 reformulated rosacea program or controlled follow-up: date unknown (Unknown; no verified successor readout) |
| Dental alignment, regeneration and repair | A sham-controlled laser study reports short-term pain relief but no root protection or faster alignment. A late-registered printed-aligner study tests material changes after human wear, not tooth movement or retention. Broader regenerative and orthodontic programs remain under watch. | Full paper/registration matching and retention outcomes: no verified release date. Completed study; numerical results and manufacturing details have no verified release date. |
An announced meeting is scheduled; a sponsor window is a forecast; a registry completion date is not a promised publication date. Unconfirmed timing stays labeled. See the date-ordered calendar and evidence rules.